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Bardet–Biedl syndrome is a rare autosomal recessive multisystem disorder caused by 
defects in genes encoding for proteins that localize to the primary cilium/basal body 
complex. Twenty-one disease-causing genes have been identified to date. It is one 
of the most well-studied conditions in the family of diseases caused by defective cilia 
collectively known as ciliopathies. In this review, we provide an update on diagnostic 
developments, clinical features, and progress in the management of Bardet–Biedl 
syndrome. Advances in diagnostic technologies including exome and whole genome 
sequencing are expanding the spectrum of patients who are diagnosed with Bardet–
Biedl syndrome and increasing the number of cases with diagnostic uncertainty. As a 
result of the diagnostic developments, a small number of patients with only one or two 
clinical features of Bardet–Biedl syndrome are being diagnosed. Our understanding of 
the syndrome-associated renal disease has evolved and is reviewed here. Novel inter-
ventions are developing at a rapid pace and are explored in this review including genetic 
therapeutics such as gene therapy, exon skipping therapy, nonsense suppression ther-
apy, and gene editing. Other non-genetic therapies such as gene repurposing, targeted 
therapies, and non-pharmacological interventions are also discussed.
Keywords: Bardet–Biedl syndrome, genetic therapies, pharmacogenomics, genome editing, targeted therapies, 
drug repurposing
inTRODUCTiOn
Bardet–Biedl syndrome (BBS), sometimes known as Laurence–Moon–Bardet-Biedl syndrome, is 
a rare autosomal recessive ciliopathy characterized by rod-cone dystrophy, learning difficulties, 
polydactyly, obesity, genital malformations, and renal abnormalities.
In the 1880s, a family with retinitis pigmentosa, obesity, and intellectual impairment was described 
by doctors Laurence and Moon. The affected family members later went on to develop a spastic 
paraparesis. In 1920 and 1922, respectively, doctors Bardet and Biedl independently described two 
families with obesity, retinitis pigmentosa, and polydactyly. From 1925, the syndrome was known as 
Laurence–Moon–Bardet–Biedl syndrome, but there was disagreement as to whether they were the 
same entity. Later, it was considered as two entities, Laurence–Moon and Bardet–Biedl syndromes, 
but mutations in known BBS genes have been seen in families with both syndromes (1, 2). Today, it 
is most usually known as BBS.
It is a pleiotropic disorder and has a prevalence of around 1:100,000 in North America and Europe, 
but it is significantly more common in certain isolated communities including Newfoundland 
(1:18,000) (2) and Kuwaiti Bedouins (1: 13,500) (3, 4). In the last 2 decades, 21 BBS genes (BBS1–
BBS21) (5–7) have been identified, mutations in which account for 80% of cases with a clinical 
diagnosis of BBS (1). Table 1 outlines the 21 BBS genes.
Mutations in BBS1 and BBS10 account for the majority of genotypes (~51 and ~20%, respectively) 
in Northern Europe and North America (4).
FigURe 1 | Clinical and diagnostic features of Bardet–Biedl syndrome. (i) Clinical features associated with Bardet–Biedl syndrome. (A–D) Typical facial features are 
often subtle and not always present. Typical facial features include malar hypoplasia, a depressed nasal bridge, deep set eyes, and retrognathia. (e) Brachydactyly. 
(F) Dental crowding. (g) High palate. (H) Rod-cone dystrophy. (ii) Diagnostic features of Bardet–Biedl syndrome. At least four major features or three major and two 
minor features are required to make a clinical diagnosis. Informed consent was obtained and republished with permission (4).
TABle 1 | Known genes causing BBS.
BBS type gene name
BBS1 BBS1
BBS2 BBS2
BBS3 ARL6
BBS4 BBS4
BBS5 BBS5
BBS6 MKKS
BBS7 BBS7
BBS8 TTC8
BBS9 BBS9
BBS10 BBS10
BBS11 TRIM32
BBS12 BBS12
BBS13 MKS1
BBS14 CEP290
BBS15 WDPCP
BBS16 SDCCA8
BBS17 LZTFL1
BBS18 BBIP1
BBS19 IFT27
BBS20 IFT172
BBS21 C8orf37
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the diagnostic criteria published by Beales et al. (9). Figure 1 dem-
onstrates the clinical features associated with BBS and highlights 
the relative frequencies at which these features are observed.
Molecular confirmation of BBS has evolved over the last decade 
from targeted sequencing of common genetic variants, including 
the common BBS1 p.M390R, BBS2 p.Y24X, BBS2 p.R275X, and 
BBS10 c.91fsX5 mutations to next-generation sequencing gene 
panels containing all known BBS genes. The frequency at which 
molecular confirmation is achieved has increased accordingly 
from approximately 40–80% (1).
The age at which patients are diagnosed is extremely vari-
able and is driven by the age of onset of symptomatic rod-cone 
dystrophy. While this may manifest in infancy, it is more usually 
seen between the ages of 5 and 10  years of age and typically 
presents with night blindness (9). Isolated polydactyly at birth 
or obesity, generally seen from infancy, do not usually prompt 
referral. Siblings of affected children are generally diagnosed 
earlier. Antenatal diagnosis is extremely rare in the absence of a 
family history, but BBS may be suspected from the identification 
of echogenic kidneys and polydactyly on ultrasound scanning. 
Children presenting with renal anomalies or renal failure may be 
diagnosed earlier than those without, but there are insufficient 
data to confirm this. A subset of individuals present with isolated 
rod-cone dystrophy with notable absence of other BBS-related 
features and are often diagnosed in adulthood. These individuals 
are now being picked up because of the introduction of panel-
based genetic testing and major diagnostic studies such as the UK 
100,000 genomes project (10) and the Deciphering Developmental 
Disorders (exome) study (11). They were previously overlooked 
as there are many causes of rod-cone dystrophy, and it was not 
understood that BBS genes could cause this feature in isolation.
Currently, diagnostic gene panels are the diagnostic tool of 
choice. The use of whole exome sequencing (WES) and whole 
genome sequencing (WGS) may increase coverage, aid in the 
discovery of novel genes, and allow for the identification of 
Bardet–Biedl syndrome proteins localize to the primary 
cilium/basal body complex, a ubiquitously expressed highly 
evolutionarily conserved organelle functioning primarily for 
cell-to-cell signaling. The genes that cause BBS can also cause 
other ciliopathies, with the classic example being CEP290, which 
can cause Joubert syndrome, Leber congenital amaurosis, Meckel 
syndrome, and Senior-Loken syndrome in addition to BBS (8).
DiAgnOSing BBS
Bardet–Biedl syndrome is a pleiotropic disorder and diagnosis 
is based on the presence of at least four major features or three 
major features and at least two minor features in accordance with 
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non-coding variants. However, along with increased expense, 
disadvantage of the more advanced diagnostic sequencing tech-
niques is the identification of pathogenic variants in non-BBS 
genes and of variants of unknown significance (VUS) in BBS 
genes (12). This can result in a diagnostic conundrum in particu-
lar where patients manifest only one or two non-specific major 
diagnostic criteria such as obesity and/or learning difficulties. The 
use of WES and WGS requires careful consenting of patients and 
having a plan in place to deal with VUS and unlooked for results.
Variable expressivity is the hallmark of BBS (8); patients 
with the same genotype and even siblings frequently manifest 
symptoms differently. As a result, although genotype–phenotype 
correlations exist on a population basis, it is not possible to make 
individual predictions about symptomatic manifestations (13). 
As a group, patients with mutations in BBS1 are usually less 
severely affected than patients with mutations in other BBS genes. 
On average, they develop visual deterioration later in life (14), are 
less likely to develop renal disease (13), and more likely to have a 
better endocrine biochemical profile (15) with a lower prevalence 
of metabolic syndrome (16, 17). It is not possible to delineate if 
this is a consequence of the common missense mutation BBS1 
p.M390R identified in 80% of Northern European patients (4) or 
if the milder phenotype is representative of an overall less severe 
phenotype associated with BBS1 mutations (17).
Suggestion that BBS would be a candidate for triallelic inher-
itance, whereby a third mutation is required to either manifest 
the condition or adding mutational load, has gathered limited 
evidence (18–20). In practice, the phenotypic variability observed 
in patients with the same genotype and within families is likely to 
reflect a complex interplay between multiple genetic factors and 
environmental influences.
In the future, it may be possible to identify phenotypic 
modifiers and further elucidate the cause for variability through 
analysis of the “Omics” (genomics, epigenomics, transcriptomics, 
proteomics, and metabolomics) whereby the complex interplay 
of genes, transcription, protein expression, and metabolism is 
considered as part of the phenotypic analysis (21, 22).
RenAl DiSeASe in BBS
Bardet–Biedl syndrome has classically been associated with poly-
cystic kidney disease, a typical feature of ciliopathies with renal 
manifestations (13, 16, 23–29). The prevalence of renal disease in 
BBS has been estimated at 53–82% (13, 16, 25). A recent study 
of 350 patients from the United Kingdom estimated that 50% of 
patients will develop functional renal disease and demonstrated 
that cystic or dysplastic disease only accounts for 30% of patients 
with renal disease, where the remainder have hydronephrosis, 
scarred or atrophic kidneys, loss of corticomedullary function, or 
developmental abnormalities (13). Around 8% of patients go on 
to develop end-stage renal disease requiring dialysis or transplan-
tation (13). The majority of patients who develop end-stage renal 
disease do so in early childhood (before the age of 5), and in most 
cases, deterioration is rapid with frequent requirement for dialy-
sis within the first year of life (13). Some patients develop sudden 
renal failure in adulthood for unknown reasons, and a further 
group of patients develop end-stage kidney disease as a result of 
comorbidities including type 2 diabetes and hypertension (13). 
The prevalence of these comorbidities is thought to be higher in 
BBS patients than the normal population and in 1 study of 69 
patients were found in 22 and 35%, respectively (17). The risk 
of type 2 diabetes relates to obesity and is treated using standard 
protocols. Many patients with structural renal abnormalities do 
not go on to develop functional renal disease (17).
The molecular mechanistic pathways leading to renal disease 
in BBS remain unelucidated (29). It has been suggested that 
aberrant mTOR signaling may contribute to the development of 
cystic kidney disease (28). Another theory proposes that ciliary 
dysfunction leads to aberrant non-canonical Wnt signaling and 
planar cell polarity, which may contribute to the development of 
cysts (30). Molecular evidence supporting these theories remains 
limited. Furthermore, they do not explain why only some patients 
develop renal dysplasia or indeed the heterogeneous types of 
renal disease developed by patients.
CURRenT MAnAgeMenT OF BBS
Bardet–Biedl syndrome is currently treated symptomatically 
focusing in particular on aggressive management of diabetes, 
hypertension, and metabolic syndrome to minimize the second-
ary impact that these conditions have on vulnerable organ systems 
already affected by BBS, in particular the eyes and kidneys (17). 
Weight management is a continual struggle for the majority of 
patients (31). Some elect to have bariatric surgery (32) while oth-
ers take antiobesity medication, but for the majority of patients, 
dietetic input provides the safest and most effective weight loss 
strategy (33).
In the UK, patients who attend the national BBS clinics are 
invited to attend a multidisciplinary clinic for annual review by a 
geneticist, ophthalmologist, nephrologist, endocrinologist, psy-
chologist, dietitian, speech and language therapist, nurse, and a 
patient support group representative. This provides a platform for 
regular review and individualized risk assessment in particular 
with reference to renal and endocrine deterioration. All patients 
are genotyped using a service-developed diagnostic gene panel. 
The clinic also provides an opportunity for research into the 
natural progression of BBS, and it is expected that patients will 
eventually be stratified according to genotype and their need for 
clinical follow-up.
FUTURe THeRAPieS FOR BBS
The last decade has seen significant advances in the development 
of therapeutic modalities, which could potentially be applicable 
to patients with BBS and related ciliopathies. However, the large 
number of disease-causing genes and private mutations, which 
are those seen in only a single family, present a unique challenge 
in developing genetic therapies for BBS (34). Figure 2 outlines 
potential future therapies, which are likely to benefit patients with 
BBS in the future.
genetic Therapies
A particular focus for therapeutic intervention in the ciliopathies 
has been the development of therapy for rod-cone dystrophy 
FigURe 2 | Future interventions and stage in the pharmacological development process. Genetic therapies and other pharmacological interventions are under 
development for BBS. Dark blue arrows demonstrate the stage to which BBS-specific interventions have been developed. Other ciliopathy relevant developments 
are indicated in light blue. The last column indicates the percentage of BBS patients who could benefit from this type of intervention. BBS, Bardet–Biedl syndrome; 
LCA, leber congenital amaurosis; PCD, primary ciliary dyskinesia; RP, retinitis pigmentosa; US, Usher syndrome.
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(34–36). The eye offers an attractive organ for therapeutic 
intervention in BBS due to the ease of access, the presence of a 
control (other) eye, the small amount of tissue that needs to be 
infiltrated, and a window of opportunity to develop treatment 
as patients typically do not develop symptoms before mid to late 
childhood (37).
Novel disease models are being generated with the potential to 
develop in vitro organ systems for the assessment of new therapies. 
A promising development is the generation of induced pluripo-
tent stem cells (38–43). These cells are generated when adult cells 
are reprogrammed and subsequently differentiated into another 
cell type through the addition of growth factors (41). A number 
of cell types have been used for reprogramming including dermal 
fibroblasts (44), renal epithelial cells (45), keratinocytes (46), and 
peripheral blood cells (47).
Urine-derived renal epithelial cells have been used to model 
ciliopathies, such as Joubert syndrome to assess the effect of 
potential therapeutics (48, 49) and BBS to derive mechanistic 
insights into disease pathogenesis (unpublished data). This is a 
particularly attractive model for many ciliopathies including BBS 
as it is non-invasive and offers an organ-specific relevant disease 
model.
To our knowledge, currently, there are no efforts in progress 
to develop genetic therapies targeted to the renal manifestations 
of BBS. This is likely to be a function of a number of issues 
including that the onset of renal manifestations is often antenatal 
precluding a therapeutic window of opportunity. Furthermore, 
the natural history of renal disease in BBS is not well understood, 
and the cause of renal disease can be both primary (e.g., cystic 
renal disease) and secondary to metabolic syndrome, hyperten-
sion, or diabetes all of which occur more frequently in BBS than 
the general population (13). In addition, the kidney is more dif-
ficult to target with genetic therapies but may prove to be a more 
amenable target for pharmacological therapies.
Gene Therapy
Traditional gene replacement therapy has achieved significant 
success in the treatment of ciliopathy-related eye diseases includ-
ing Usher syndrome and Leber congenital amaurosis in recent 
years (50–52). The premise involves the generation of viral or 
non-viral vectors carrying a wild-type gene of choice with the aim 
of integrating the gene into the host genome. The highest chance 
of success is achieved in diseases where only a small amount of 
healthy gene expression is required to generate a phenotypic 
effect (53).
A major challenge in developing genetic therapies for BBS is 
the generation of a long lasting therapy. A successful example 
of this is the retinal gene therapy (Luxturna), which has been 
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successfully developed for RPE65-associated Leber congenital 
amaurosis. It is likely to obtain approval from the Food and Drug 
Administration (FDA) in 2018 as the first gene therapy for ocular 
disease. Extensive optimization was required before RPE65 gene 
therapy could be launched for FDA approval due to concerns 
about the sustainability and long-term maintenance of visual 
function (36, 37, 54).
Work on retinal gene replacement therapy for BBS is ongoing 
in animal models, and recent efforts were published demonstrat-
ing encouraging results in knock-in mouse models with the 
most common genotype in humans BBS1 p.M390R (55). Viral 
AAV vectors were generated containing the wild-type Bbs1 
construct and injected subretinally rescuing BBSome formation 
and rhodopsin localization and showing trends toward improved 
electroretinogram function in mice (55).
Challenges of developing safe and effective gene therapy 
include ensuring that the gene expression is proportionate to the 
requirements of the host organism avoiding overexpression and 
thus cell toxicity (36, 51, 55), identifying an appropriate time to 
administer therapy (36) (in the case of rod-cone dystrophy ideally 
before photoreceptor death), avoiding generation of an immune 
response, and developing safe and effective vectors (53).
Readthrough Therapy
Readthrough therapy exploits the natural inconsistency of the 
genetic proofreading mechanism in the process of RNA transla-
tion into protein (56). Nonsense mutations account for an esti-
mated 11% of the total mutational load in BBS (own unpublished 
data) and lead to premature termination of protein synthesis 
and subsequent degradation via nonsense mediated decay (57). 
Readthrough therapy acts by destabilizing the translational 
ribosome’s response to a nonsense mutation, hence allowing the 
insertion of a near cognate amino-acyl-tRNA. This allows trans-
lation to continue and a full-length protein to be produced (58). 
The effect mimics that of a missense mutation in the same locus, 
which may result in a less severe clinical phenotype. Readthrough 
therapy has been applied to a number of different conditions and 
been tested in clinical trials for both cystic fibrosis (59–61) and 
Duchenne muscular dystrophy (62, 63). The effect of readthrough 
therapy has been assessed on some ciliopathies at the preclinical 
stage including primary ciliary dyskinesia (64), Usher syndrome 
(65), and retinitis pigmentosa (RP2) (66).
Exon Skipping Therapy
Exon skipping therapy operates at the level of RNA transcription 
allowing the transcriptional machinery to “skip” exons contain-
ing undesirable genetic sequences (67, 68). Antisense oligonu-
cleotides are designed to target an exon/intron of interest. This 
allows for a novel splicing product that may retain much of its 
wild-type function depending on the quantity and importance 
of functional motifs coded for by the exon. This form of genetic 
therapy is often used to target mutations, which disrupt the 
genetic reading frame and may otherwise result in a complete 
lack of functional protein. Successful application of exon skip-
ping therapy has been developed to the level of clinical trials for 
Duchenne muscular dystrophy and spinal muscular atrophy (69, 
70). Exon skipping therapy for ciliopathies has been developed 
to the stage of preclinical trials for Leber Congenital Amaurosis 
and Usher syndrome (67, 71). In BBS, this form of therapy could 
benefit up to 9% of patients. The primary challenge is that many 
mutations suitable for exon skipping therapy in BBS are private 
and thus require truly individualized therapy. The common 
frameshift mutation in BBS (BBS10 c.91fsX5) is not a suitable 
candidate as the gene contains only two exons.
Genome Editing
Genome engineering offers an attractive future prospect in the 
management of genetic diseases, allowing DNA to be deleted, 
replaced, or corrected (72). Targeted endonucleases create 
double-stranded breaks at specific points in the genome allowing 
for DNA repair, which can restore the wild-type genotype (43). 
Promising results have been achieved in cells from patients with 
the motile ciliopathy primary ciliary dyskinesia where ciliation 
was restored on replacement of the wild-type DNAH11 sequence 
(73). Preclinical work and clinical trials for other diseases using 
genome editing techniques are progressing with significant 
advances in animal models of epidermolysis bullosa (74). Initial 
reports of successful gene editing in humans include gene editing 
on embryos at risk for hypertrophic cardiomyopathy caused by 
MYBPC3 mutation (75) and treatment-resistant leukemia (75, 
76). The potential applications are promising, but this technique 
requires significant refinement in specificity, efficacy, and safety 
before this can be applied in a clinical setting. Off target effects, 
whereby genome engineering may erroneously occur on an 
unintended gene causing DNA damage are a major challenge in 
bringing this technique forward (72).
While genome editing can be used to target specific organ sys-
tems, it can also be applied ex vivo to correct or insert mutations 
to directly comparable cell types which apart from the mutation 
of interest are genetically identical, thus eliminating genetic 
background noise and providing an ideal model system (77).
non-genetic Personalized Therapies
Targeted Therapies
A novel development in the therapeutic landscape for BBS is the 
application of targeted drug therapies. An example of this is the 
ongoing work on the melanocortin receptor agonists as potential 
therapeutic intervention against obesity in BBS (78). Our under-
standing of how aberrant BBS proteins cause signal disruption is 
still evolving; however, there is emerging evidence suggesting that 
BBS results in defects in the hypothalamic leptin–melanocortin 
axis (79). This in turn causes leptin resistance culminating in 
obesity (78).
Seo et al. demonstrated that intravenous administration of a 
melanocortin receptor agonist decreased both body weight and 
food intake in wild-type and Bbs knockout mice (78). A phase 2/3 
clinical trial is in process assessing the effect of novel melanocor-
tin receptor agonist setmelanotide on obesity in BBS and other 
forms of syndromic obesity (80).
Drug Repurposing
Future therapies may include repurposing of drugs, which are 
already FDA approved. Early work on Bbs zebrafish indicated 
that rapamycin may be a candidate for rectifying the renal cystic 
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phenotype (81). Further work on higher animals has not been 
published, but drug repurposing offers an attractive and eco-
nomical option for management in a clinical setting since the cost 
and failure rate of developing novel therapeutics remain high.
nOn-PHARMACOlOgiCAl FUTURe 
inTeRvenTiOnS
A major challenge in any clinical service is harnessing the advances 
in technology and managing increasing clinical pressures. To this 
end, the UK National BBS clinic is implementing several new 
strategies to meet the increasing need for transparency and access 
to clinical services.
There is an increasing move to offer patients easy access to 
their medical notes and to data sharing within the UK National 
Health Service to optimize patient management (82). These issues 
are being addressed in the UK National BBS clinic through the 
development of a cloud-based medical notes system, which is 
accessible to all clinicians in the service. In the future, patients 
will be able to access their personal medical records through 
smart phones or other devices, so that medical information can 
be accessed wherever they are.
Telemedicine and virtual clinics, whereby patient consulta-
tions can take place via a screen in the patient’s own home, are 
an attractive alternative for BBS patients who are stable and in 
particular for those with visual impairment where travel can pre-
sent a considerable obstacle to attending hospital appointments. 
It also offers an advantage to clinicians where hospital resources 
and clinic space are at a premium.
PHARMACOgenOMiCS
Pharmacogenomic profiling, whereby the effect of the genome on 
drug response is determined, could offer significant advantages 
to those patients with complex medical needs who are subject 
to polypharmacy (83) including BBS patients. Although several 
private companies offer pharmacogenomics gene panels, this is 
not currently available in the UK National Health Service, and 
the evidence base is unclear for many of these private initiatives. 
However, there is a growing evidence base supporting pharma-
cogenomic profiling, and this is likely to become available in the 
National Health Service in the coming years.
COnClUSiOn
Bardet–Biedl syndrome provides a robust model disease for 
future opportunities in genetic and non-genetic therapeutic man-
agement of rare diseases. A significant advantage in the United 
Kingdom is the presence of the national BBS clinics, which offer 
a centralized hub for clinical and scientific expertise. The multio-
rgan effects and wide range of genes and mutation types mean 
that a number of different genetic therapeutic modalities must be 
considered, as well as non-genetic pharmacological interventions 
and non-pharmacological approaches to optimize management 
of this rare disease in the future.
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